BRIM8: Vemurafenib in high risk melanoma patients
Dr Karl Lewis - University of Colorado Denver, Colorado, USA
BRIM8: Vemurafenib in high risk melanoma patients ( Dr Karl Lewis - University of Colorado Denver, Colorado, USA )
11 Sep 2017
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma
Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma ( Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
11 Sep 2017
Expert commentary on melanoma immunotherapy latest
Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard
Expert commentary on melanoma immunotherapy latest ( Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard )
11 Sep 2017
Vemurafenib for high risk melanoma patients
Dr Karl Lewis - University of Colorado Denver, Colorado, USA
Vemurafenib for high risk melanoma patients ( Dr Karl Lewis - University of Colorado Denver, Colorado, USA )
11 Sep 2017
Dabrafenib plus trametinib for stage III mutant melanoma
Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
Dabrafenib plus trametinib for stage III mutant melanoma ( Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
11 Sep 2017
Nivolumab vs ipilimumab for high risk melanoma patients
Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Nivolumab vs ipilimumab for high risk melanoma patients ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
11 Sep 2017
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection
Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
11 Sep 2017
The METRIC trial of trametinib, five years on
Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany
The METRIC trial of trametinib, five years on ( Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany )
10 Sep 2017
New strategies in melanoma care
Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands
New strategies in melanoma care ( Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands )
10 Sep 2017
Reduced work ability in cancer survivors
Dr Cecilie Kiserud - Oslo University Hospital, Oslo, Norway
Reduced work ability in cancer survivors ( Dr Cecilie Kiserud - Oslo University Hospital, Oslo, Norway )
9 Sep 2017
Problems with survivorship care in Europe
Prof Francesco De Lorenzo - University of Naples Federico II, Naples, Italy
Problems with survivorship care in Europe ( Prof Francesco De Lorenzo - University of Naples Federico II, Naples, Italy )
9 Sep 2017
Underprovision and inequality of specialised cancer care
Dr Emmanouil Saloustros - General Hospital of Heraklion 'Venizelio', Crete, Gree...
Underprovision and inequality of specialised cancer care ( Dr Emmanouil Saloustros - General Hospital of Heraklion 'Venizelio', Crete, Greece )
9 Sep 2017